(ABN 79 000 248 304)
Consolidated preliminary half year report
For the half year ended 31 December 2007
Compared to the half year ended 31 December 2006
28 February, 2008
No interim dividend has been declared for the current period, and no dividend was declared or paid for the
Net tangible assets (NTA) per share as at 31 December, 2007: $0.089. [2006: $0.054]
The attached accounts have been reviewed.
Commentary on the Company’s operations for the six months to 31 December, 2007 is included on pages 2 and
3 of this report.
Revenues from continuing operations
up 103.6 to
Loss from continuing operations after tax
up 81.9 to
Net Profit attributable to members
up n/a to
We are pleased to present to you the half-yearly results to December 31, 2007, and report on the substantial
progress in the clinical, research and corporate activities of ChemGenex Pharmaceuticals.
The names of the company’s directors in office during the period and until the date of this report are listed below.
Directors were in office for the entire period unless otherwise stated.
The profit for the period of $4.1 million includes a “one off” gain of $12.4 million associated with the disposal of
metabolic syndrome assets through an In Specie Distribution to shareholders completed in December 2007. Loss
from the continuing oncology research business was $6.9 million, 82% higher than for the corresponding period
(last year $3.8 million). Revenue from ordinary activities of $0.6 million increased by 103% over the
corresponding period (last year $0.3 million).
Review of Operations
The half-year to December 31, 2007 saw significant advances in the clinical development of the company’s lead
agent, omacetaxine mepesuccinate (formerly homoharringtonine) and a range of corporate changes desi